INSIGHTS ON DRUG DEVELOPMENT

• Transformative Innovation: Advancing Drug Development Using In Silico Modeling

  Explore how predictive modeling and in silico strategies can turn complex data into actionable insights that accelerate drug development and reduce risk across the development lifecycle.

• Expanding Translational Research Concepts With Genedata Profiler

  The biopharma industry leverages Genedata Profiler to integrate, curate, and analyze diverse R&D data, enabling collaborative, compliant, and AI-driven translational research to optimize drug development.

• The 5 Ws Of A Human Factors Strategy

  A human factors strategy ensures medical products are safe, effective, and compliant by integrating user-focused design early, reducing risks, and optimizing regulatory approval processes.

• Is Lipinski's Rule Of Five Still Relevant In Drug Development?

  Some drugs violate multiple Ro5 elements but remain developable, while some molecules adhere strictly to the Ro5, but their properties are not conducive to development.

• Selecting A CDMO For Custom Activated PEGs

  1/27/2026

  Custom-activated PEGs require thoughtful planning and precise analytical control. Discover key considerations for selecting a partner capable of supporting scalable, compliant PEGylation.

• Your AKTA Oligosynt™ System : It's More Than A Machine

  2/9/2026

  Discover how early choices in oligo synthesis workflows shape performance. Learn what to consider across design, reagents, and system optimization to build a process ready for smooth scale‑up.

• Formulation Development Of Enterically Protected Spray Dried Dispersions

  11/17/2025

  Adrulipase spray-dried dispersions were evaluated to create an orally delivered, enteric-protected enzyme. The lead formulation provided the best acid protection, rapid release, and stability.

• Particles In High Concentration Biotherapeutics

  8/7/2025

  Examine advanced analytical solutions that detect, characterize, and mitigate particle formation in high-concentration biotherapeutics caused by protein aggregation and surfactant degradation.

• Complementary Methodologies For Analysis Of NISTmAb Impurities

  2/27/2026

  Gain insight into how SEC and CE‑SDS complement each other to assess monoclonal antibody size variants, offering stronger insight into aggregates, fragments, and overall purity.